news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
The poster entitled “Perception of Quality of Life Among People Experiencing or Having Experienced a Clostridium difficile Infection in the United States: Qualitative Review of Respondents Verbatim” will present the key results of a quality of life survey conducted among 350 US patients with C.difficile infection.
The presentation will be done by Paul Feuerstadt, MD, Principal Co-investigator of the study. Don’t miss it!
You can also download the poster as a PDF here.